Exact Sciences (EXAS) Misses Q1 EPS by 21c, Updates Guidance

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.54), $0.21 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $707 million versus the consensus estimate of $688.78 million.

GUIDANCE:

Exact Sciences sees FY2025 revenue of $3.07-3.12 billion, versus the consensus of $3.9 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance